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a b s t r a c t
The response to treatment and overall survival of patients with AML is heterogeneous.
Prognostic factors are urgently needed in order to be able to better predict treatment
outcomes. The aim of the present work was to study telomere length and human telo-
merase reverse transcriptase (hTERT) level in acute myeloid leukemia and to detect if
these parameters might be useful in providing insight into the clinical outcome of AML
patients. ELISA technique was used to measure hTERT level quantitative PCR for measu-
ring telomere length. The study included 70 individuals, 50 patients with acute myeloid
leukemia and twenty healthy individuals with comparable age and sex. There was statis-
tically significant higher level of hTERT and lower RTL in patients than controls. The
patients were treated according to the standard chemotherapy protocol for induction
and they were followed up by bone marrow examination. Mean hTERT level in patients
who did not achieve complete hematological remission was statistically significant hig-
her than that in patients who achieved complete hematological remission (48.87 and
34.32 respectively) (z = 1.98, p = 0.048). Mean RTL in patients who achieved remission
was higher than that in patients who did not achieve remission (0.56 and 0.37 respecti-
vely). However, it did not reach statistical significance. Median survival time in patients
who achieved remission was statistically significant longer than that in those who did
not achieve remission (26 ms and 4 ms respectively).
It was found that both relative telomere length and hTERT could be used for assessing
clinical behavior and predicting treatment outcome in AML patients.
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Acute myelogenous leukemia (AML) is a malignant disease
of the bone marrow in which hematopoietic precursors are
arrested in an early stage of development. Despite enor-
mous insights into the molecular mechanisms of acute
myeloid leukemia (AML) pathophysiology, this disease is
still fatal in the majority of patients, highlighting the urgent
need for novel biomarkers useful in AML prognosis and
therapy [1, 2].
Telomeres are specialized nucleoprotein structures at the
ends of chromosomes; their function is to protect chromo-
somes from DNA breakage and to prevent chromosome
fusion. Without new synthesis, telomeres undergo progres-
sive shortening with each cell division, leading to replicative
senescence of cells. Shortening of telomeres can result in
telomere end fusions and increase chromosomal instability
which is a key initiating event in numerous cancers [3].
Telomerase is an enzyme that extends telomeric repeats
on the ends of chromosomes. Activation of telomerase
enzyme is therefore required for cells to overcome replica-
tive senescence and to be able to divide indefinitely.
Telomerase activity is expressed in germ cells and is present
at low level in stem cells, but is usually absent in most
somatic cells. Conversely, in immortal cancer cells, telomer-
ase is reactivated, and telomeres are not shortened, suggest-
ing that telomere elongation might be an essential step in
tumor formation [4, 5].
Recently genes encoding three major components of
human telomerase (TA) have been cloned: human telomer-
ase RNA component (hTR), human telomerase reverse
transcriptase (hTERT), and telomerase-associated protein
1 (TAP1). TERT is a telomerase catalytic subunit that is
considered as the key component for the control of telomer-
ase activity [6, 7].
Telomere length (TL) is a key determinant of telomere
function. Accurate techniques to measure TL in human
tissues have provided a greater understanding of the role of
telomeres in the progression to malignancy [8].
Targeting the hTERT catalytic subunit as anticancer
therapy is theoretically tumor-specific and might be less
toxic due to its specific expression in tumor and highly
proliferating cells compared to other normal cells. Various
newly discovered agents represent interesting anti-hTERT
candidates for clinical drug development [9].
The aim of the present study was to study baseline
telomere length and human telomerase reverse transcrip-
tase (hTERT) level in acute myeloid leukemia and to detect
if these parameters might be useful in predicting response
to therapy in acute myeloid leukemia patients.
Subjects
The study included seventy individuals. Fifty newly diag-
nosed patients with AML and twenty age and sex matched
normal healthy individuals as a control group. They were
enrolled in the study after the consent of the Ethical
Committee of the Medical Research Institute.The age of AML patients ranged from twenty three to
seventy one years with a mean age of 50.8  12.97 years.
Twenty-four (48%) patients were males and 26 (52%) were
females, with male to female ratio of 0.9.
Patients were treated according to the standard conven-
tional chemotherapy protocol of AML. The treatment proto-
col entailed the following drugs: Daunorubicin (60 mg/m2/
day for 3 days), and continuous infusion of Cytosine-
Arabinoside (100 mg/m2/day for 7 days) [2]. Patients unfit for
receiving the induction cycle were excluded from the study.
Patients were assessed for response to induction therapy
at the time of blood count recovery by bone marrow
examination. They were divided into two groups: responders
who achieved complete hematological remission after
induction chemotherapy and non-responders who did not
achieve complete hematological remission after induction
chemotherapy. The term complete remission generally
refers to morphologic complete remission, defined by red
blood cell transfusion independence, an absolute neutrophil
count of more than 1000/ml and a platelet count of 100 000/
ml or greater and the presence of less than 5% blasts in
a bone marrow aspirate sample with marrow spicules and
with a count of at least 200 nucleated cells, absence of
blasts with Auer rods, and absence of extramedullary
leukemia [2].
Methods
All subjects participating in this study were subjected to the
following:
 Thorough history taking, thorough clinical examination,
routine work up including liver and kidney function tests
[10], radiological work up (chest X-ray, U/S abdomen
&pelvis and ECHO)
 Diagnostic laboratory investigations including, complete
blood picture (CBP) [11], bone marrow examination [12],
and immunophenotyping [13]
 Quantitative assessment of hTERT by ELISA [14].
Kit was purchased from GenWay
 quantitative PCR for measuring telomere length [15].
 Genomic DNA from patients was extracted using
QIAamp DNA Blood Mini Kit (50) from Qiagen.
 Relative telomere length (RTL) were determined using
real-time PCR.
Results
The present study included fifty patients with acute myeloid
leukemia, and twenty healthy individuals with comparable
age and sex (control group).
The age of AML patients ranged from twenty three to
seventy one years with a mean age of 50.8  12.97 years.
Twenty-four patients were males (48%) and 26 were females
(52%), with male to female ratio of 0.9. AML patients
included 36 patients aged <60 years (72%), and 14 patients
aged 60 years (28%).
Fig. 1 – Correlation between hTERT and RTL in AML patients
(r = 0.36, p = 0.011). Interpretation of rs: Weak (0.1–0.24);
Intermediate (0.25–0.74); Strong (0.75–0.99)
Table I – Comparison of hTERT level and RTL in AML
patients according to remission state
Items Responders Non-responders z p
hTERT (ng/ml)
 Mean 34.32 48.87 1.98 0.048
 SD 23.6 25.16
Relative telomere length
 Mean 0.56 0.37 1.59 0.110
 SD 0.36 0.30
Z: Mann–Whitney test.
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cation system using morphologic and cytochemical criteria.
Thirty-one patients were M2 (62%), 9 patients were M1
(18%), 6 patients were M4 (12%). Other types (M3, M5, M6,
and M7) were represented by only one case for each.
Laboratory findings
In AML patients, hemoglobin concentration (Hb) ranged
from 4 g/dl to 11.5 g/dl, with mean value of 7.5  2 g/dl. Red
blood cell count (RBC) ranged from 1.7 to 4 (1012/L), mean
value of 2.5  0.6 (1012/L). Platelet count (Plt) ranged from
5 to 186 (109/L), with mean value of 34.1  33.4 (109/L).
Total leucocytic count (TLC) ranged from 0.3 to 340 (109/L),
with mean value of 24.1  50.9 (109/L). Blast % ranged from
0% to 95%, with mean value of 50.5  24%.
Conventional cytogenetic analysis was done for 18 patients
only in the present study. Thirteen patients showed normal
karyotype. Meanwhile, monosomy 7 was detected in 3 patients,
trisomy 21 in one patient, and t(15,17) in one patient.
After induction chemotherapy, patients were followed up
by bone marrow examination to determine patient's
response to therapy. Complete remission was achieved in
nineteen patients (38%), and partial remission in seven
patients (14%). Meanwhile, nine patients were resistant to
therapy, and fifteen patients died during the first 28 days.
During follow up, nine out of the nineteen patients who
achieved CR relapsed.
The mean age of patients who achieved CR after induc-
tion chemotherapy (responders) was 45 years. It was statis-
tically significant lower than the mean age of patients who
did not achieve CR (nonresponders) which was 54 years
(t = 2.592, p = 0.013).
Serum level of hTERT in AML patients and control subjects
Serum hTERT level in the control group ranged from 2.04 to
11.11 ng/ml, with a mean level of 5.06  2.32 ng/ml.
Whereas, serum level in AML patients ranged from 4.9 to
98 ng/ml, with a mean level of 43.3  25.4 ng/ml. There was
a statistically significant higher level of hTERT in patients
than controls (z = 6.107, p = 0.000).
The mean serum hTERT level was higher in patients
aged 60 years than in patients aged <60 years (44 and
43.1 ng/ml respectively), and in females compared to males
(43.6 and 42.9 ng/ml respectively). However, this difference
did not reach statistical significance.
Relative telomere length by real-time PCR in AML patients and
control
Relative telomere length (RTL) in AML patients ranged from
0.01 to 1.1. Mean level was 0.4  0.3. While, in control group,
it ranged from 0.85 to 6.77 with mean telomere length of
3.75. RTL was statistically significant lower in patients than
control (z = 6.384, p = 0.000).
The mean RTL was lower in patients aged 60 years than
in patients aged <60 years (0.4 and 0.5 respectively), and in
females compared to males (0.4 and 0.5 respectively). How-
ever, this difference did not reach statistical significance.Correlation between hTERT and RTL
There was a negative correlation between serum level of
hTERT and the relative telomere length (p = 0.011). Level of
correlation was intermediate as rs level was 0.36, as illu-
strated in Fig. 1.
No statistically significant relation was detected between
different FAB subtypes and serum HTERT level or RTL
(p = 0.628, p = 0.475 respectively). However, when FAB sub-
types M4 and M5 were grouped together as one group, AML
patients with more differentiated subtypes (M4 and M5) had
statistically significant shorter telomere length than AML
patients with less differentiated subtypes (M1, M2, and M3).
Relative telomere length was (0.149 and 0.49 respectively)
(p = 0.011). But no statistical significant difference between
both groups as regard hTERT level.
Serum hTERT level and relative telomere length in relation to
response to induction chemotherapy
As demonstrated in Table I, the mean serum hTERT level at
diagnosis in patients who did not achieve complete remis-
sion (non-responders) was statistically significant higher
than that in patients who achieved complete remission
Fig. 3 – ROC curve showing cut off value of 0.5 for RTL as a
predictive value for AML outcomeFig. 2 – ROC curve showing cut off value of 57.57 ng/ml for
hTERT as a predictive value for AML outcome
Fig. 4 – Comparison between responders and non-
responders regarding survival (p = 0.001). Case Processing
Summary: AML patients in remission: events number = 6,
censored number = 13; AML patients not in remission:
events number = 30, censored number = 1
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p = 0.048).
Mean RTL in patients who achieved complete remission
(responders) was higher than that in patients who did not
achieve complete remission (non-responders) (0.56 and 0.37
respectively). There was no statistical significant difference
between both groups (z = 1.59, p = 0.110).
Using ROC curve, a cut off value of 57.57 ng/ml for
baseline serum level of hTERT at diagnosis was calculated
which divided the patients into responders and non-respon-
ders after receiving the induction chemotherapy. Area under
the curve (AUC) = 0.603 (overall accuracy = 60.3%). This
means that, in AML patients with value less or equal to
57.57 ng/ml, 60.3% of patients will achieve complete remis-
sion (sensitivity was 69.2%, and specificity was 56%).
Similarly, a cut off value of 0.5 was calculated for
baseline RTL. AUC = 0.556 (overall accuracy = 55.6%) with
sensitivity 50% and specificity 56%. This means that, in AML
patients with value equal or more than 0.5, 55.6% of patients
will achieve complete remission. As demonstrated in
Figs. 2 and 3.
Survival analysis
During duration of our study (30 months), number of events
(death) was 36 and censored cases were 14 (total number of
our cases = 50).
Using Kaplan–Meier estimate, the median survival time
for all AML patients in the study was 10 months (range:
5.271–14.729 months) 95% Confidence Interval.
Median survival time in patients 60 years was shorter
than that in patients <60 years (8 ms and 10 ms respec-
tively), but there was no statistically significant difference asregard mean survival time between both age groups (Log
Rank (Mantel–Cox) test: Chi-Square = 1.272, p = 0.259).
Median survival time was statistically significant higher
in patients who achieved complete remission (26 months)
compared to those who did not achieve complete remission
(4 months) (Log Rank (Mantel–Cox) test: Chi-Square = 38.952,
p = 0.001). This difference is illustrated in Fig. 4.
Median survival time in relapsed patients was shorter
than that in non relapsed patients (20 ms, 26 ms respec-
tively). There was a statistical significant difference in
median survival time in both groups (Log Rank (Mantel–Cox)
test: Chi-Square = 2.609, p = 0.050).
Median survival time in patients with hTERT level higher
than cut-off level was shorter than median survival time in
Fig. 6 – Survival comparison according to RTL (cut-off level)
in AML patients (p = 0.002). Case Processing Summary: AML
patients with higher RTL than cut-off: events number = 10,
censored number = 13; AML patients with lower RTL than
cut-off: events number = 26, censored number = 1
Fig. 5 – Survival comparison according to hTERT level (cut-
off level) in AML patients (p = 0.017). Case Processing
Summary: AML patients with higher level than cut-off:
events number = 19, censored number = 1; AML patients
with lower level than cut-off: events number = 17, censored
number = 13
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There was a statistical significant difference in median
survival time in both groups (Log Rank (Mantel–Cox) test:
Chi-Square = 5.653, p = 0.017). Similarly, Median survival
time in patients with relative telomere length lower than
cut-off value was shorter than median survival time in
patients with higher value (6 ms, and 14 ms respectively).
There was a statistical significant difference in median
survival time in both groups. There was a statistical sig-
nificant difference in median survival time in both groups
(Log Rank (Mantel–Cox) test: Chi-Square = 9.305, p = 0.002).
This is shown in Figs. 5 and 6.Discussion
The response to treatment and overall survival of patients
with AML is heterogeneous. A number of prognostic factors
have been described for AML, including age, performance
status, and karyotype. These prognostic factors are urgently
needed in order to be able to better predict treatment
outcomes in defined subgroups of patients [16].
Telomere shortening and telomerase activity has been
suggested to be of prognostic value in various human
hematopoietic malignancies [17–19].
In the present study, telomere length and human telo-
merase reverse transcriptase (hTERT) level were measured
in acute myeloid leukemia patients to detect if these
parameters might be useful in predicting response to
therapy in AML patients.
Conventional cytogenetic analysis was done for 18
patients only. Chromosomal abnormalities were detected in
40% of patients (three patients had monosomy 7, one
patient had trisomy 21, and one patient had t(15,17)) and
59% of AML patients (thirteen patients) had normal karyo-
type pattern. This finding is in line with the findings of
Meng et al. 2013 [20].
The patients were treated according to the standard
chemotherapy protocol for induction in AML. They were
then assessed for response to induction therapy by bone
marrow examination at the time of blood count recovery
after chemotherapy. They were divided into two groups:
responders, who achieved hematological CR and non-
responders who did not achieve hematological CR.
All patients were followed for 30 months (the duration of
the study).
Although, several studies have reported telomerase
expression in acute and chronic leukemia [17–19]. However,
up to our knowledge no large studies have assayed telomer-
ase in quantitative manner.
The present study looked comprehensively into measure-
ment of level of serum hTERT in AML patients and correlated
it with treatment outcome. So that, we could understand the
prognostic role of telomerase and to predict the efficacy of
antitelomerase drugs currently in development.
In the current study, serum hTERT level was significantly
higher in AML patients compared to control group. This is
consistent with previous studies that reported increased
serum hTERT level in several solid tumors as in lung cancer
[21, 22], colorectal cancer [23], breast carcinoma [24], laryn-
geal squamous cell carcinoma [25], in gynecological malig-
nancies [26], in hepatocellular carcinoma [27], and in
hematologic neoplasia [28–30]. As most malignant tumors
showed increased hTERT activity, it may contribute as part
of a multistep process, to human carcinogenesis, as it
results in increased telomerase activity. The results of this
study is highly supported by the work of Engelhardt et al.
[19] who revealed significantly increased telomerase in
diagnostic specimens compared with specimens obtained
after treatment initiation, which correlated with the disap-
pearance of leukemic cells and with the attainment of
remission. In addition, Hartmann et al. in 2005 analyzed
hTERT different splicing patterns in AML samples, and
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expression of the active hTERT splicing variant. Also, Porika
et al. 2011 [31] observed that serum hTERT could have
a potential application as a novel biomarker for breast
cancer diagnosis.
As opposed to the finding in the present work, Greiner
et al. [32] reported that, hTERT mRNA was expressed in only
21% of new diagnosed AML patients [32]. Also, Xu et al. [33]
showed that hTERT expression was only detectable in AML
samples with intermediate or high levels of telomerase
activity. This opposing finding could be attributed to differ-
ent methodologies used. Thus, a direct comparison of the
results of various studies is not possible.
In the present study, the mean telomere length in AML
patients was significantly shorter, than in healthy control
group. This finding is in accordance with previous reports
[28, 34, 35]. This is supported by the work of Boultwood
et al. [36] who reported that progressive telomere shortening
in patients with chronic myelogeneous leukemia in late
chronic phase could be linked to up-regulation of telomer-
ase activity and disease evolution in AML [36].
Regarding age, AML patients <60 years had longer
telomere length than patients 60 years but the difference
in telomere length was not statistically significant. This
finding is expected as telomeres within hematopoietic cells
and other somatic tissues progressively shorten with age [8].
However, Hartmann et al. 2005 [28] found significantly
shorter telomere length in the younger group of patients,
their finding could be attributed to a higher proportion of
karyotypic abnormalities in the younger patients than in the
older patients in their population.
A statistically significant negative correlation was found
between serum hTERT level and relative telomere length in
the present study. This result is in line with the study of
Tukun et al. 2006 [37]. This observation could be attributed
to the fact that telomerase reactivation is a requirement – if
not cause – for unlimited proliferation, which is an essential
characteristic of cancer cells. This unlimited dividing capa-
city provided by telomerase leads to progressive telomere
shortening [37].
Serum hTERT and RTL and response to therapy
In the present study, it was observed that serum hTERT
level at diagnosis was significantly lower in patients who
achieved complete hematological remission than patients
who did not achieve complete hematological remission
suggesting that hTERT level may act as a predictive marker
for the treatment outcome. This finding is supported by the
work of Porika et al. 2011 [31] who suggested that pretreat-
ment serum hTERT levels showed a significant correlation
with clinical stage in patients with cancer breast.
Relative telomere length at diagnosis was longer in
patients who achieved complete remission than in patients
who did not achieve complete remission. However, the
difference did not reach statistical significance. Further
studies with larger number of patients are needed to verify
its significance.
Engelhardt [19] observed that, longer telomeres were
found after induction chemotherapy in AML and MDSpatients, most likely due to the loss of the leukemic clone
(with shorter telomeres) and the emergence of normal
hematopoietic cells (with longer telomeres) [19].
Serum hTERT level and relative telomere length were
compared between patients who survived till the end of the
study (total duration of the study was 30 ms) and patients
who died during the study. A highly statistical significant
difference between both groups as regards mean hTERT
level and mean RTL (p = 0.001, p = 0.001) was found. These
observations also suggest that both high hTERT level and
short telomere could be considered as poor prognostic
factors.
Patients were followed for 30 months (the duration of the
study). No statistically significant difference was found
between young adult and elderly AML patients in mean
survival time using Kaplan–Meier estimate.
This result is not comparable to those obtained in other
studies [38, 39] who reported higher incidence of treatment-
related mortality in elderly group. However, patients who
achieved CR had a statistically significant younger age than
patients who did not achieve CR (t = 2.592, p = 0.013).
These results are in line with studies supporting old age
as cause of poor clinical outcome and poor prognostic factor
[38, 39].
On the other hand, a high statistically significant differ-
ence was detected in median survival time in patients who
achieved complete remission compared to those who did
not achieve complete remission (26 months and 4 months
respectively). The same was observed in relapsed and non
relapsed patients as there was a statistically significant
difference in median survival time (20 months and 26
months respectively).
Also, survival time was studied in relation to the cut-off
value of both hTERT and relative telomere length.
A statistically significant longer survival time was observed
in patients with hTERT level lower than or equal to the cut-
off point and RTL higher than or equal to the cut-off point.
Targeting the hTERT catalytic subunit as anticancer
therapy is theoretically tumor-specific and might be less
toxic due to its specific expression in tumor and highly
proliferating cells compared to other normal cells. Various
newly discovered agents represent interesting anti-hTERT
candidates for clinical drug development [40, 9].
The telomere and telomerase interactions appear to be
an essential determinant for proliferative capacities of
tumor cells. It has been known that telomerase activity
provides the ability of proliferation to the malignant cell;
thus, targeting of tumor cells by inhibiting telomerase may
be an effective therapy.
Authors' contributions/Wkład autorów
According to order.
Conflict of interest/Konflikt interesu
None declared.
a c t a h a e m a t o l o g i c a p o l o n i c a 4 6 ( 2 0 1 5 ) 3 0 4 – 3 1 1310Financial support/Finansowanie
None declared.
Ethics/Etyka
The work described in this article has been carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments invol-
ving humans; EU Directive 2010/63/EU for animal experi-
ments; Uniform Requirements for manuscripts submitted to
Biomedical journals.
r e f e r e n c e s / p i s m i e n n i c t w o
[1] Nebbioso A, Benedetti R, Conte M, Iside C, Altucci L. Genetic
mutations in epigenetic modifiers as therapeutic targets in
acute myeloid leukemia. Expert Opin Ther Targets 2015;30
(May):1–16.
[2] Baer MR, Greer JP. Acute myeloid leukaemia in adults. In:
Greer JP, Foerster J, Luken JN, editors. Wintrobe's
clinical haematology. 13th ed., Philadelphia, USA:
Lippincott William's and Wilkin's publishers; 2013. p.
1843–1889.
[3] Charles H. Telomeres, telomerase, and cancer. N Engl J Med
2000;342:1282–1283.
[4] Klapper W, Krams M, Qian W, Janssen D, Parwaresch R.
Telomerase activity in B-cell non-Hodgkin lymphomas is
regulated by hTERT transcription and correlated with
telomere-binding protein expression but uncoupled from
proliferation. Br J Cancer 2003;89:713–719.
[5] Wong JMY, Collins K. Telomerase maintenance and disease.
Lancet 2003;362:293.
[6] Bryce LA. Mapping of the gene for the human telomerase
reverse transcriptase, hTERT, to chromosome 5p15.33 by
fluorescence in situ hybridization. Neoplasia 2000;2:
197–201.
[7] Sabah M, Robert C, Mary L, Elaine K. Immunohistochemical
detection of hTERT protein in soft tissue sarcomas:
correlation with tumor grade. Appl Immunohistochem Mol
Morphol 2006;14(2):198–202.
[8] Baird DM. New developments in telomere length analysis.
Exp Gerontol 2005;40:363–368.
[9] Olaussen KA, Dubrana K, Domont J, Spano J, Sabatier L,
Charles J. Telomeres and telomerase as targets for
anticancer drug development. Crit Rev Oncol Hematol
2006;57(3):191–214.
[10] Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical
chemistry and molecular diagnostics, 4th ed., St Louis:
Elsevier Saunders Company; 2006: 797–825 (renal function
tests), 604–614 (liver function tests).
[11] Howven B. The blood cell count. In: Rawan RM, van
Assendelft OW, Perston FE, editors. Advanced laboratory
methods in haematology. 1st ed., Great Britain: Library of
Congress Cataloging; 2002. p. 19–44.
[12] Bates I. Bone marrow biopsy. In: Lewis SM, Bain BJ, Bates I,
editors. Dacie and Lewis practical haematology. 9th ed.,
London: Library of Congress Cataloging; 2001. p. 101–114.
[13] Matutes E, Morilla R, Catovsky D. Immunophenotyping. In:
Lewis SM, Bain BJ, Bates I, editors. Dacie and Lewis practical
haematology. 9th ed., London: Library of Congress
Cataloging; 2001. p. 297–314.[14] Leffell MS. Immunity and immunological assays. In: Noe
DA, Rock RC, editors. Laboratory medicine. 1st ed., USA:
Library of Congress Cataloging; 1994. p. 75–97.
[15] Cawthon RM. Telomere measurement by quantitative PCR.
Nucleic Acids Res 2002;30(10):e47.
[16] Sekeres MA, Peterson B, Dodge RK, et al. Differences in
prognostic factors and outcomes in African Americans and
whites with acute myeloid leukemia. Blood 2004;103:4036.
[17] Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres
and telomerase in hematologic neoplasia. Oncogene
2002;21:680–687.
[18] Samassekou O, Ntwari A, Hébert J, Yan J. Individual
telomere lengths in chronic myeloid leukemia. Neoplasia
2009;11:1146–1154.
[19] Engelhardt M, Mackenzie K, Drullinsky P, Silver R.
Telomerase activity and telomere length in acute and
chronic leukemia, pre and post-ex vivo culture. Cancer Res
2000;60(13):610–617.
[20] Meng CY, Noor PJ, Ismail A, Ahid MF, Zakaria Z. Cytogenetic
profile of de novo acute myeloid leukemia patients in
Malaysia. Int J Biomed Sci 2013;9(1):26–32.
[21] White LK, Wright WE, Shay HW. Telomerase inhibitors.
Trends Biotechnol 2001;19:114–120.
[22] Peter JFS, Roderick HJB, Thomas GS, et al. Elevated hTERT
mRNA levels: a potential determinant of bronchial
squamous cell carcinoma (in situ). Int J Cancer
2004;109:412–417.
[23] Liliana T, Enrica R, Salvatore P, et al. Relationship between
tumor and plasma levels of hTERT mRNA in patients with
colorectal cancer: implications for monitoring of neoplastic
disease. Clin Cancer Res 2008;14:7444–7451.
[24] Salhab M, Jiang WG, Newbold RF, et al. The expression of
gene transcripts of telomere-associated genes in human
breast cancer: correlation with clinico-pathological
parameters and clinical outcome. Breast Cancer Res Treat
2008;109:35–46.
[25] Li YR, Wu JM, Wang L, et al. Human telomerase reverse
transcriptase expression and its clinical significance in
laryngeal squamous cell carcinoma. Acta Otolaryngol
2005;125:409–414.
[26] Miura N, Kanamori Y, Takahashi M, et al. A diagnostic
evaluation of serum human telomerase reverse
transcriptase mRNA as a novel tumor marker for
gynecologic malignancies. Oncol Rep 2007;17:541–548.
[27] Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase
reverse transcriptase messenger RNA as a novel tumor
marker for hepatocellular carcinoma. Clin Cancer Res
2005;11:3205–3209.
[28] Hartmann U, Brummendorf TH, Balabanov S, Thiede C,
Illme T, Schaich M. Telomere length and hTERT expression
in patients with acute myeloid leukemia correlates with
chromosomal abnormalities. Haematologica 2005;90:
307–316.
[29] Seol JG, Kim ES, Park WH, Jung CW, Kim BK, Lee YY.
Telomerase activity in acute myelogenous leukemia:
clinical and biological implications. Br J Haematol
1998;100:156–165.
[30] Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and
gene regulation of the catalytic subunit of telomerase
(hTERT). Gene 2001;269:1–12.
[31] Porika M, Tippani R, Bollam SR, Panuganti SD, Thamidala C,
Abbagani S. Serum human telomerase reverse
transcriptase: a novel biomarker for breast cancer
diagnosis. Int J Clin Oncol 2011;16:617–622.
[32] Greiner J, Ringhoffer M, Taniguchi M, et al. mRNA
expression of leukemia-associated antigens in
patients with acute myeloid leukemia for the
development of specific immunotherapies. Int J Cancer
2004;108:704–711.
a c t a h a e m a t o l o g i c a p o l o n i c a 4 6 ( 2 0 1 5 ) 3 0 4 – 3 1 1 311[33] Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and
the expression of telomerase components in acute
myelogenous leukaemia. Br J Haematol 1998;102:
1367–1375.
[34] Swiggers SJ, Kuijpers MA, de Cort MJ, Beverloo HB, Zijlmans
JM. Critically short telomeres in acute myeloid leukemia
with loss or gain of parts of chromosomes. Genes
Chromosomes Cancer 2006;45:247–256.
[35] Aalbers AM, Calado RT, Young NS, Zwaan CM. Telomere
length and telomerase complex mutations in pediatric
acute myeloid leukemia. Leukemia 2013;27:1786–1789.
[36] Boultwood J, Peniket A, Watkins F, et al. Telomere length
shortening in chronic myelogenous leukemia is associatedwith reduced time to accelerated phase. Blood 2000;96:
358–361.
[37] Tukun A, Akay G, Kutlay N. Telomere and telomerase in
hematological malignancies. Turk J Hematol 2006;23:77–83
[Review article].
[38] Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in
the elderly. Semin Oncol 2008;35:430–438.
[39] Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid
leukaemia in the elderly: a review. Br J Haematol
2011;152:524–542.
[40] Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres
and telomerase in hematologic neoplasia. Oncogene
2002;21(4):680–687.
